Clinical overview of MDM2/X-targeted therapies

A Burgess, KM Chia, S Haupt, D Thomas… - Frontiers in …, 2016 - frontiersin.org
MDM2 and MDMX are the primary negative regulators of p53, which under normal
conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid …

Cell-penetrating peptides (CPPs): An overview of applications for improving the potential of nanotherapeutics

K Desale, K Kuche, S Jain - Biomaterials Science, 2021 - pubs.rsc.org
In the field of nanotherapeutics, gaining cellular entry into the cytoplasm of the target cell
continues to be an ultimate challenge. There are many physicochemical factors such as …

Recent advances in the use of cell-penetrating peptides for medical and biological applications

SB Fonseca, MP Pereira, SO Kelley - Advanced drug delivery reviews, 2009 - Elsevier
The selective permeability of the plasma membrane prohibits most exogenous agents from
gaining cellular access. Since many therapeutics and reporter molecules must be …

Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition

MS Dai, SX Zeng, Y Jin, XX Sun… - Molecular and cellular …, 2004 - Am Soc Microbiol
The p53-MDM2 feedback loop is vital for cell growth control and is subjected to multiple
regulations in response to various stress signals. Here we report another regulator of this …

Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation

S Kurki, K Peltonen, L Latonen, TM Kiviharju, PM Ojala… - Cancer cell, 2004 - cell.com
Abstract Nucleophosmin (NPM, B23) is an abundant nucleolar phosphoprotein involved in
ribosome biogenesis, and interacts with tumor suppressor proteins p53 and Rb. Here we …

The multiple levels of regulation by p53 ubiquitination

JT Lee, W Gu - Cell Death & Differentiation, 2010 - nature.com
Abstract p53 is a central integrator of a plethora of signals and outputs these signals in the
form of tumor suppression. It is well accepted that ubiquitination plays a major part in p53 …

p53-independent functions of the p19ARF tumor suppressor

JD Weber, JR Jeffers, JE Rehg, DH Randle… - Genes & …, 2000 - genesdev.cshlp.org
The p19ARF tumor suppressor antagonizes Mdm2 to induce p53-dependent cell cycle
arrest. Individual TKO (triple knock out) mice nullizygous for ARF, p53, and Mdm2 develop …

Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function

C Korgaonkar, J Hagen, V Tompkins… - … and cellular biology, 2005 - Taylor & Francis
The ARF tumor suppressor is a nucleolar protein that activates p53-dependent checkpoints
by binding Mdm2, a p53 antagonist. Despite persuasive evidence that ARF can bind and …

Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus

S Llanos, PA Clark, J Rowe, G Peters - Nature cell biology, 2001 - nature.com
The alternative product of the human INK4a/ARF locus, p14 ARF, has the potential to act as
a tumour suppressor by binding to and inhibiting the p53 antagonist MDM2. Current models …

[HTML][HTML] Identification of a ubiquitin–protein ligase subunit within the CCR4–NOT transcription repressor complex

TK Albert, H Hanzawa, YIA Legtenberg… - The EMBO …, 2002 - embopress.org
The RING finger protein CNOT4 is a component of the CCR4–NOT complex. This complex is
implicated in repression of RNA polymerase II transcription. Here we demonstrate that …